Consolidated Statements of Income (Loss) - USD ($) shares in Millions, $ in Millions	3 Months Ended	6 Months Ended
Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Net revenues	$ 4,701	$ 5,720	$ 9,766	$ 11,370
Cost of sales	2,640	2,865	5,357	5,676
Gross profit	2,061	2,855	4,409	5,694
Research and development expenses	290	469	607	901
Selling and marketing expenses	710	944	1,481	1,902
General and administrative expenses	316	363	645	729
Other asset impairments, restructuring and other items	715	419	1,422	659
Goodwill impairment	120	6,100	300	6,100
Legal settlements and loss contingencies	20	324	(1,258)	344
Other income	(96)	(24)	(299)	(96)
Operating income (loss)	(14)	(5,740)	1,511	(4,845)
Financial expenses, net	236	238	507	445
Income (loss) before income taxes	(250)	(5,978)	1,004	(5,290)
Income taxes (benefit)	(76)	(22)	(30)	32
Share in (profits) losses of associated companies, net	(8)	14	66	7
Net income (loss)	(166)	(5,970)	968	(5,329)
Net Income (loss) attributable to non-controlling interests	10		24	(4)
Net income (loss) attributable to Teva	(176)	(5,970)	944	(5,325)
Dividends on preferred shares	65	65	130	130
Net income (loss) attributable to ordinary shareholders	$ (241)	$ (6,035)	$ 814	$ (5,455)
Earnings (loss) per share attributable to ordinary shareholders:
Basic	$ (0.24)	$ (5.94)	$ 0.80	$ (5.37)
Diluted	$ (0.24)	$ (5.94)	$ 0.80	$ (5.37)
Weighted average number of shares (in millions):
Basic	1,018	1,017	1,018	1,016
Diluted	1,018	1,017	1,020	1,016

Impairments restructuring and others.

No definition available.

Name:	teva_ImpairmentsRestructuringAndOthers
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The net proceeds or assets obtained in excess of (less than) the net carrying amount of assets recorded, or assets distributed and liabilities assumed less than (in excess of) litigation reserves extinguished, in settlement of a litigation matter. Represents (for other than an insurance entity in its normal claims settlement process), the amount of income (expense) recognized in the period to settle pending or threatened litigation and insurance claims and the aggregate amount provided for estimated restructuring charges, remediation costs, and asset impairment loss during an accounting period. Generally, these items are either unusual or infrequent, but not both (in which case they would be extraordinary items).

+ References

No definition available.